<?xml version="1.0" encoding="UTF-8"?>
<ref id="B110">
 <label>110.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Miyata</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Harakuni</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Sugawa</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Sattabongkot</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Kato</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Tachibana</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Adenovirus-vectored 
   <italic>Plasmodium vivax</italic> ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine
  </article-title>. 
  <source>Vaccine.</source> (
  <year>2011</year>) 
  <volume>29</volume>:
  <fpage>2720</fpage>â€“
  <lpage>6</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.083</pub-id>
  <?supplied-pmid 21315699?>
  <pub-id pub-id-type="pmid">21315699</pub-id>
 </mixed-citation>
</ref>
